You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 195971 - 195980 of 207712 results
  1. STTR Phase I:Rapid-Release Cell Culture Platform for Flow Cytometry

    SBC: CROSSMHV, L.L.C            Topic: BT

    The broader impact of this Small Business Technology Transfer (STTR) Phase I project is to enable new health diagnostics, advance personalized medicine, and accelerate research for various diseases, including many types of cancers. Many methods used to diagnose disease are limited by the methods used to process patient samples. Commonly used processes can disrupt or destroy disease markers present ...

    STTR Phase I 2022 National Science Foundation
  2. STTR Phase I:Protective T Cell Vaccine for SARS CoV-2(COVID-19)

    SBC: MBF THERAPEUTICS INC            Topic: PT

    The broader impact /commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to develop a fundamentally different next-generation SARS CoV-2 vaccine that addresses current gaps in efficacy, safety, and national and global distribution ofvaccines. The rapid global emergence of the highly infectious delta variant underscores the importance of T cell immunity, increas ...

    STTR Phase I 2022 National Science Foundation
  3. STTR Phase I:Scaling and Optimizing Manufacturing Methods for Germicidal Optical Fibers (GOF) to prevent disease-causing biofilms in tight channels

    SBC: OPTICAL WATERS LLC            Topic: M

    The broader impact of this Small Technology Transfer Research (STTR) Phase 1 project is to advance the development of germicidal optical fibers (GOF). GOFs side emit ultraviolet-C (UV-C) radiation along their entire length like a glowstick. Their use in tight channels of homes, businesses, and hospitals can eliminate pathogenic bacteria and viruses that cause operational issues, infections and eve ...

    STTR Phase I 2022 National Science Foundation
  4. Novel platform for optimizing AAV transgene expression to improve efficacy of ocular gene therapies

    SBC: Epigenos Bioscience, Inc.            Topic: 100

    Abstract Gene therapy applications based on adeno-associated virus (AAV) have demonstrated promise in clinical applications for the treatment of diverse genetic diseases highlighted by the recent FDA approval of AAV vector formulations as new drugs for ocular and neurological diseases. In these instances, along with all applications of clinical AAV gene therapy to date, constitutive transcription ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Development and Evaluation of Rosette Array Technology for HumanNeurodevelopmental Toxicity Screening

    SBC: Neurosetta LLC            Topic: 113

    Project Summary Pre-clinical and pre-field toxicology testing of new drugs and chemicals does not routinely include direct assessment of human developmental neurotoxicity (DNT). Current standards for DNT testing require use of animal models with limited throughput and significant differences from human central nervous system (CNS) development. As such, many chemical products have required post-app ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Gectosome Therapy for Cardiovascular Diseases

    SBC: Vesicle Therapeutics Inc.            Topic: NHLBI

    Project Summary Vesicle Therapeutics Inc aims to develop and commercialize a new therapy for homozygous familial hypercholesterolemia (hoFH). A majority of hoFH is caused by mutations in both alleles of the gene encoding the LDL receptor (LDLR). Since the efficacy of both statins and PCSK9 antibody therapies largely depends on functional LDL receptors, patients with hoFH show limited responses to ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Klebsiella pneumoniae is an encapsulated human pathogen capable of causing a myriad of human infections. Recently, K. pneumoniae has also emerged as one the most common causes of secondary bacterial pneumonia in COVID-19 patients. Over the last 40 years, K. pneumoniae has evolved into two distinct pathotypes, known as classical K. pneumoniae (cKp) and hypervirulent K. pneumoniae (h ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Multi-species Vaccine for Prevention of Bacterial Otitis Media

    SBC: CLARAMETYX BIOSCIENCES, INC            Topic: NIDCD

    Project SummaryOtitis media (OM) is a spectrum of clinical entities that presents a tremendous global health burden; in fact, OM is the most common infectious bacterial disease in children. Sequelae of OM include hearing impairment, developmental and language delays, and even death, with nearly $5B spent annually in the US alone for medical/surgical management and lost wages for working parents. T ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Enhancing the Engraftment of Microglia for the Treatment of Neurological Disease

    SBC: Novoglia, Inc.            Topic: NINDS

    There are no effective treatments for microgliopathies, a class of neurodegenerative disorders that are caused by the absence or misfunction of specialized cells in the brain, called microglia. One potential strategy to treat patients with a microgliopathy is to replace their diseased microglia with new cells. The NovoGlia technology platform uses induced pluripotent stem cells to generate new mic ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Sourcerer IC: A Web-Based Integrative Multi-Modal Workflow for Epilepsy Surgical Planning

    SBC: Brain Electrophysiology Laboratory Company, LLC            Topic: 106

    Abstract The overarching goal of this project is to create software that improves the use of intracranial EEG to qualify patients with medication-resistant epilepsy for neurosurgery. One million people in the US suffer from continual seizures that are not controlled by medication. The current estimate is that half of these could be treated effectively by surgical resection of the epileptic cortica ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government